Institute of Basic and Translational Medicine & Shaanxi Key Laboratory of Brain Disorders, Xi'an Medical University, Xi'an, PR China.
J Alzheimers Dis. 2021;79(4):1429-1442. doi: 10.3233/JAD-200851.
Alzheimer's disease (AD) is a chronic neurodegenerative disease that has been recognized as one of the most intractable medical problems with heavy social and economic costs. Amyloid-β (Aβ) has been identified as a major factor that participates in AD progression through its neurotoxic effects. The major mechanism of Aβ-induced neurotoxicity is by interacting with membrane receptors and subsequent triggering of aberrant cellular signaling. Besides, Aβ transporters also plays an important role by affecting Aβ homeostasis. Thus, these Aβ receptors and transporters are potential targets for the development of AD therapies. Here, we summarize the reported therapeutic strategies targeting Aβ receptors and transporters to provide a molecular basis for future rational design of anti-AD agents.
阿尔茨海默病（AD）是一种慢性神经退行性疾病，已被认为是社会和经济成本最高的最棘手的医学问题之一。淀粉样蛋白-β（Aβ）已被确定为通过其神经毒性作用参与 AD 进展的主要因素。Aβ 诱导的神经毒性的主要机制是通过与膜受体相互作用，随后触发异常的细胞信号转导。此外，Aβ 转运体也通过影响 Aβ 动态平衡发挥重要作用。因此，这些 Aβ 受体和转运体是开发 AD 治疗方法的潜在靶点。在这里，我们总结了针对 Aβ 受体和转运体的报告治疗策略，为未来合理设计抗 AD 药物提供了分子基础。
